Non-canonical NF-κB signaling activation and regulation: Principles and perspectives

Immunological Reviews

Volumn 244, Issue 1, 2011, Pages 44-54

  Razani, Bahram ^a,b   Reichardt, Anna Devi ^a,b   Cheng, Genhong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

NF B inducing kinase; Non canonical NF B; TRAF2; TRAF3

Indexed keywords

CD40 LIGAND; CXCL13 CHEMOKINE; CYCLOHEXIMIDE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; LYMPHOTOXIN BETA RECEPTOR; NUCLEAR FACTOR KAPPA B INDUCING KINASE; PHOSPHOTRANSFERASE; PROTEASOME; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE MYELOMA; NEGATIVE FEEDBACK; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS; RING FINGER MOTIF; SJOEGREN SYNDROME; SOMATIC MUTATION; UBIQUITINATION;

ANIMALS; DIMERIZATION; ENZYME STABILITY; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; MICE; NF-KAPPA B; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054854922     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01059.x     Document Type: Article

References (83)

1. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002;3:958-965.
2. Coope HJ, et al. CD40 regulates the processing of NF-[kappa]B2 p100 to p52. EMBO J 2002;21:5375-5385.
3. Dejardin E, et al. The Lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways. Immunity 2002;17:525-535.
4. Novack DV, et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003;198:771-781.
5. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-κB-inducing kinase. Immunity 2004;21:477-489.
6. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-κB2 p100 processing and long lasting NF-κB activation. J Biol Chem 2003;278:36005-36012.
7. Senftleben U, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001;293:1495-1499.
8. Qing G, Qu Z, Xiao G. Stabilization of basally translated NF-κB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-κB2 p100. J Biol Chem 2005;280:40578-40582.
9. Xiao G, Fong A, Sun S-C. Induction of p100 processing by NF-κB-inducing kinase involves docking IκB kinase α (IKKα) to p100 and IKKα-mediated phosphorylation. J Biol Chem 2004;279:30099-30105.
10. Solan NJ, Miyoshi H, Carmona EM, Bren GD, Paya CV. RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem 2002;277:1405-1418.
11. Zarnegar BJ, et al. Noncanonical NF-[kappa]B activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9:1371-1378.
12. Vallabhapurapu S, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-[kappa]B signaling. Nat Immunol 2008;9:1364-1370.
13. Vince JE, et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 2007;131:682-693.
14. Varfolomeev E, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 2007;131:669-681.
15. Gardam S, et al. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood 2011;117:4041-4051.
16. Kato M, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-716.
17. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75kDa tumor necrosis factor receptor. Cell 1994;78:681-692.
18. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995;83:1243-1252.
19. Deng L, et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000;103:351-361.
20. Kayagaki N, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 2007;318:1628-1632.
21. Yang Y, Fang S, Jensen J, Weissman A, Ashwell J. Ubiquitin protein ligase activity of IAPs and their degradation in proteosomes in response to apoptotic stimuli. Science 2000;288:874-877.
22. Huang HK, Joazeiro C, Bonfoco E, Kamada S, Leverson J, Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 2000;275:26661-26664.
23. Bertrand M, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700.
24. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-κB pathway. J Biol Chem 2007;282:3688-3694.
25. Hauer J, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005;102:2874-2879.
26. Kim J-Y, et al. TNFα-induced noncanonical NF-{kappa}B activation is attenuated by RIP1 through stabilization of TRAF2. J Cell Sci 2011;124:647-656.
27. Gentle IE, et al. In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-κB and activation of caspase-8. J Biol Chem 2011;286:13282-13291.
28. Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-β receptor. J Biol Chem 2010;285:17148-17155.
29. Xu LG, Shu HB. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF- κB activation and IL-10 production. J Immunol 2002;169:6883-6889.
30. Akiba H, et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κB-inducing kinase. J Biol Chem 1998;273:13353-13358.
31. Vince JE, et al.TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha J Cell Biol 2008;182:171-184.
32. Oganesyan G, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006;439:208-211.
33. Saha SK, et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J 2006;25:3257-3263.
34. Li T, Morgan MJ, Choksi S, Zhang Y, Kim Y-S, Liu Z-G. MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKK[alpha] during macrophage differentiation. Nat Immunol 2010;11:799-805.
35. Lin X, Mu Y, Cunningham ET, Marcu KB, Geleziunas R, Greene WC. Molecular determinants of NF-kappa B-inducing kinase action. Mol Cell Biol 1998;18:5899-5907.
36. Xiao G, Harhaj EW, Sun S-C. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell 2001;7:401-409.
37. Fong A, Sun S-C. Genetic evidence for the essential role of β-transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J Biol Chem 2002;277:22111-22114.
38. Lin L, Ghosh S. A glycine-rich region in NF-κB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol 1996;16:2248-2254.
39. Belich M, Salmeron A, Johnston L, Ley S. TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105. Nature 1999;397:363-368.
40. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C. NF-κB p105 is a target of IκB kinases and controls signal Induction of Bcl-3-p50 complexes. EMBO J 1999;18:4766-4778.
41. Mordmuller B, Krappmann D, Esen M, Wegener E, Scheidereit C. Lymphotoxin and lipopolysaccharide induce NF-κB-p52 generation by a co-translational mechanism. EMBO J 2003;4:82-87.
42. Atkinson P, Coope HJ, Rowe M, Ley S. Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-κB2 p100 to p52. J Biol Chem 2003;278:51134-51142.
43. Basak S, et al. A fourth IκB protein within the NF-κB signaling module. Cell 2007;128:369-381.
44. Garceau N, et al. Lineage-restricted function of nuclear factor κB-inducing kinase (Nik) in transducing signals via CD40. J Exp Med 2000;191:381-386.
45. Didonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997;388:548-554.
46. Zandi E, Rothwarf D, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997;91:243-252.
47. Xiao G, et al. Retroviral oncoprotein tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα. EMBO J 2001;20:6805-6815.
48. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-κB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 2008;105:3503-3508.
49. Renner F, Schmitz ML. Autoregulatory feedback loops terminating the NF-κB response. Trends Biochem Sci 2009;34:128-135.
50. Liao G, Zhang M, Harhaj E, Sun SC. Regulation of the NF-κB-inducing kinase by tumor necrosis factor recptor-associated factor 3-induced degradation. J Biol Chem 2004;279:26243-26250.
51. Razani B, et al. Negative feedback in noncanonical NF-κB signaling modulates NIK stability through IKKα-mediated phosphorylation. Sci Signal 2010;3:ra41.
52. Yeh WC, et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997;7:715-725.
53. Xu Y, Cheng GH, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996;5:407-415.
54. Caamano JH, et al. Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 1998;187:185-196.
55. Miyawaki S, et al. A new mutation, Aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur J Immunol 1994;24:429-434.
56. Franzoso G, et al. Mice deficient in nuclear Factor (NF)-κB/p52 present with defects in humoral responses, Germinal Center Reactions, and Splenic Microarchitecture. J Exp Med 1998;187:147-159.
57. Yin L, et al. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science 2001;291:2162-2165.
58. Dougall W, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
59. Futterer A, Mink K, Luz A, Kosco-Vilbois M, Pfeffer K. The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998;9:59-70.
60. Sasaki Y, Casola S, Kutok J, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004;173:2245-2252.
61. Shulga-Morskaya S, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004;173:2331-2341.
62. Kawabe T, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-178.
63. Akiyama T, et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008;29:423-437.
64. Mebius R. Organogenesis of lymphoid tissues. Nat Rev Immunol 2003;3:292-303.
65. Bonizzi G, et al. Activation of IKKα target genes depends on recognition of specific [kappa]B binding sites by RelB:p52 dimers. EMBO J 2004;23:4202-4210.
66. Do R, Hatada E, Lee H, Tourigny M, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192:953-964.
67. Sasaki Y, et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc Natl Acad Sci USA 2008;105:10883-10888.
68. Gerondakis S, Strasser A. The Role of Rel/NF-κB transcription factors in B lymphocyte surivival. Sem Immunol 2003;15:159-166.
69. Lind EF, et al. Dendritic cells require the NF-κB2 pathway for cross-presentation of soluble antigens. J Immunol 2008;181:354-363.
70. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-κB pathway activation in multiple myeloma. Blood 2010;115:3541-3552.
71. Compagno M, et al. Mutations of multiple genes cause deregulation of NF-[kgr]B in diffuse large B-cell lymphoma. Nature 2009;459:717-721.
72. Pham LV, et al. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways. Blood 2011;117:200-210.
73. Rosebeck S, et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-κB activation. Science 2011;331:468-472.
74. Annunziata CM, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-130.
75. Keats JJ, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007;12:131-144.
76. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007;27:253-267.
77. Gardam S, Sierro F, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008;28:391-401.
78. Zhang J, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
79. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-1319.
80. Groom J, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68.
81. Enzler T, et al. Alternative and classical NF-κB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006;25:403-415.
82. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Veis Novack D. NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005;115:1848-1854.
83. Maniatis T. Catalysis by a multiprotein IκB kinase complex. Science 1997;278:818-819.